Article
Potential Adiponectin Receptor Response Modifier Therapeutics
13 Aug 2019
Abstract excerpt
Many human diseases may benefit from adiponectin replacement therapy, but due to pharmacological disadvantages of the intact protein, druggable options focus on peptidic and small molecule agonists of the adiponectin receptor. Peptide-based adiponectin replacement drug leads are derived from, or resemble, the active site of globular adiponectin. ADP355, the first-in-class such peptide, exhibits low nanomolar...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
